130 related articles for article (PubMed ID: 3909329)
1. Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis.
Winslade NE; Smith IL; Simons GW; Swanson DJ; Vigano A; Wels PB; Schentag JJ
Rev Infect Dis; 1985; 7 Suppl 4():S716-23. PubMed ID: 3909329
[TBL] [Abstract][Full Text] [Related]
2. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
Birolini D; Moraes MF; de Souza OS
Chemotherapy; 1989; 35 Suppl 1():49-57. PubMed ID: 2659290
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.
Smith PF; Ballow CH; Booker BM; Forrest A; Schentag JJ
Clin Ther; 2001 Aug; 23(8):1231-44. PubMed ID: 11558860
[TBL] [Abstract][Full Text] [Related]
4. Aztreonam plus clindamycin versus tobramycin plus clindamycin in the treatment of intraabdominal infections.
Williams RR; Hotchkin D
Rev Infect Dis; 1991; 13 Suppl 7():S629-33. PubMed ID: 2068472
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of aztreonam in infected patients.
Mattie H; Matze-van der Lans A
J Antimicrob Chemother; 1986 Feb; 17(2):215-9. PubMed ID: 3700287
[TBL] [Abstract][Full Text] [Related]
6. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
Nolen TM; Phillips HL; Hall HJ
Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321
[TBL] [Abstract][Full Text] [Related]
7. Aztreonam plus clindamycin vs. tobramycin plus clindamycin for the treatment of intraabdominal infections.
Birolini D; Moraes MF; de Souza OS
Rev Infect Dis; 1985; 7 Suppl 4():S724-8. PubMed ID: 3909330
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis.
Reed MD; Aronoff SC; Stern RC; Yamashita TS; Myers CM; Friedhoff LT; Blumer JL
Pediatr Pulmonol; 1986; 2(5):282-6. PubMed ID: 3774385
[TBL] [Abstract][Full Text] [Related]
9. Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
Henry SA
Rev Infect Dis; 1985; 7 Suppl 4():S729-33. PubMed ID: 3909331
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of aztreonam in patients with gram-negative infections.
Janicke DM; Cafarell RF; Parker SW; Apicella MA; Jusko WJ
Antimicrob Agents Chemother; 1985 Jan; 27(1):16-20. PubMed ID: 4039117
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
Rivera-Vazquez CR; Ramirez-Ronda CH; Rodriguez JR; Saavedra S
Chemotherapy; 1989; 35 Suppl 1():89-100. PubMed ID: 2659296
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with aztreonam in Germany and Austria.
Stille W; Gillissen J
Rev Infect Dis; 1985; 7 Suppl 4():S825-30. PubMed ID: 3909342
[TBL] [Abstract][Full Text] [Related]
13. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
Schentag JJ; Vari AJ; Winslade NE; Swanson DJ; Smith IL; Simons GW; Vigano A
Am J Med; 1985 Feb; 78(2A):34-41. PubMed ID: 3881947
[TBL] [Abstract][Full Text] [Related]
14. Aztreonam pharmacokinetics in burn patients.
Friedrich LV; White RL; Kays MB; Brundage DM; Yarbrough D
Antimicrob Agents Chemother; 1991 Jan; 35(1):57-61. PubMed ID: 2014982
[TBL] [Abstract][Full Text] [Related]
15. Summary of worldwide clinical trials of aztreonam in patients with lower respiratory tract infections.
Swabb EA; Cone CO; Muir JG
Rev Infect Dis; 1985; 7 Suppl 4():S675-8. PubMed ID: 3909323
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.
Horrevorts AM; Degener JE; Dzoljic-Danilovic G; Michel MF; Kerrebijn KF; Driessen O; Hermans J
Chest; 1985 Aug; 88(2):260-4. PubMed ID: 4017681
[TBL] [Abstract][Full Text] [Related]
17. [Bacteriological, pharmacokinetic and clinical studies on aztreonam in the pediatric field. Pediatric Study Group of Aztreonam].
Fuyii R; Meguro H; Arimasu O; Sunakawa K; Ishizuka Y; Nakazawa S; Sato H; Narita A; Matsumoto K; Suzuki H
Jpn J Antibiot; 1985 Nov; 38(11):3195-216. PubMed ID: 3912524
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.
Burgess DS; Summers KK; Hardin TC
Clin Ther; 1999 Nov; 21(11):1882-9. PubMed ID: 10890260
[TBL] [Abstract][Full Text] [Related]
19. Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients.
Ariza J; Xiol X; Esteve M; Fernández Bañeres F; Liñares J; Alonso T; Gudiol F
Hepatology; 1991 Jul; 14(1):91-8. PubMed ID: 2066075
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of carumonam in patients with renal insufficiency.
Horber F; Egger HJ; Weidekamm E; Dubach UC; Frey FJ; Probst PJ; Stoeckel K
Antimicrob Agents Chemother; 1986 Jan; 29(1):116-21. PubMed ID: 3729324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
